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 Editorial 
 Aldo  Clerico and  Mario  Plebani 
 Biomarkers for sepsis: an unfinished journey 
 In 1992, an expert panel from the American College of Chest 
Physicians and the Society of Critical Care Medicine [ 1 ] pro-
duced a consensus statement focused on the definitions 
for sepsis and organ failure. Indeed, the term sepsis has 
long been used interchangeably with bacteremia, severe 
sepsis, or even septic shock, causing some confusion and 
difficulty in comparing results from diffe rent studies [ 2 ]. 
This consensus document stated for the first time the defi-
nitions and criteria with the aim to distinguish between 
infection, bacteremia, systemic inflammation response 
syndrome (SIRS), sepsis, severe sepsis, septic shock, and 
sepsis-induced hypotension ( Table 1 ). The clinical pres-
entation of sepsis in adults can be hardly distinguishable 
from other non-infective conditions, which share a sys-
temic inflammatory response and are collectively named 
SIRS [ 2 ,  3 ]. From a clinical point of view, it is important 
to note that, although SIRS and sepsis have similar clini-
cal presentation, these two conditions can require differ-
ent treatments. Indeed, sepsis always requires antibiotic 
therapy optimized with regard to the choice of specific 
agent(s); conversely, antibiotic treatment may be contrain-
dicated for some clinical conditions related to SIRS [ 3 ]. 
 Sepsis is still a relevant clinical problem. The preva-
lence of SIRS is very high, affecting one third of all in-hos-
pital patients and  > 50% of all patients on intensive care 
unit (ICU); in surgical ICU patients, SIRS occurs in  > 80% 
patients [ 2 ]. In such patients, sepsis evolves to severe 
sepsis in  > 50% of cases, whereas the evolution to severe 
sepsis in non-ICU patients is ~25% [ 2 ]. Severe sepsis 
and septic shock occur in 2% – 3% of ward patients and 
10% – 15% of ICU patients, and 25% of patients with severe 
sepsis suffer from septic shock  [ 2 ]. 
 Sepsis is a leading cause of mortality in critically ill 
patients [ 3 ,  4 ], with a mortality risk ranging from 40% to 
70%, and septic shock is the most common cause of death 
in the modern ICU [ 3 ]. Considering that the delay in the 
diagnosis and initiation of antibiotics has been shown 
to increase mortality in septic patients [ 3 ], the ability 
to accurately distinguish between SIRS and sepsis has 
become one of the most important goals in medicine [ 4 ]. 
Unfortunately, there is no  “ gold standard ” for the diag-
nosis of sepsis. As a result, it is not surprising that there 
is a considerable debate regarding the search of reliable 
biomarkers to achieve this goal. 
 From a clinical viewpoint, a reliable biomarker for 
sepsis should improve the diagnosis, risk stratification, 
and/or therapeutic decision-making in septic patients. 
Then again, from a pathophysiologic viewpoint, a vali-
dated group of biomarkers promise to transform sepsis 
from a pathophysiologic syndrome to a group of distinct 
clinical disorders [ 5 ]. Unfortunately, there is a plethora of 
biomarkers proposed in this field, thus suggesting that a 
reliable biomarker for sepsis has never been found [ 4 – 8 ]. 
Indeed, the complex pathophysiology of sepsis involves 
many active substances (such as cellular mediators, neuro-
hormones, or cytokines), which are related to coagulation, 
complement activation, inflammation, apoptosis, and 
many other cellular and tissue effects. Moreover, the sys-
temic nature of sepsis, which involves multiple organs, 
can trigger the release of several tissue-specific biomark-
ers, even including the cardiospecific biomarkers, brain 
natriuretic peptide (BNP), and cardiac troponins [ 9 – 11 ]. 
 In this issue of Clinical Chemistry and Laboratory Medi-
cine , Di Somma et al. [ 12 ] provide an overview about the 
potential clinical usefulness of some biomarkers of sepsis. 
This opinion article represents a synopsis of the lectures on 
biomarkers and sepsis of the Third Italian GREAT Network 
Congress, which was held in Rome, 15 – 19 October 2012. In 
ref. [ 12 ], the authors discuss not only the biomarkers already 
standardized and actually used in clinical practice but also 
some biomarkers that are still tested for experimental use. 
 According to ref. [ 12 ], the rapid diagnosis of sepsis in 
emergency departments is often difficult because the symp-
toms are rather not specific. Among the huge number of 
biomarkers proposed [ 4 – 8 ,  12 ], only procalcitonin (PCT) 
complies with most of the desirable preanalytical, analyti-
cal, and postanalytical features for an ideal laboratory bio-
marker ( Table 2 ). Indeed, PCT can be assayed by means of 
sensitive and precise immunometric methods using several 
automated platforms, which allow the measurement of 
serum PCT with a turnaround time compatible with the 
rapid diagnosis indispensable in the emergency depart-
ment [ 13 – 15 ]. Moreover, some recent systematic review and 
meta-analyses, including also an economic evaluation, indi-
cated that PCT-guided antibiotic therapy is associated with a 
reduction in antibiotic therapy that, under certain assump-
tions, may reduce the overall costs of care [ 16 – 18 ]. Another 
meta-analysis [ 19 ], involving 1959 neonates, evaluated the 
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 Term  Definition and criteria 
 1. Infection  Inflammatory response to the presence of microorganisms or invasion of normally sterile tissue by 
these organisms 
 2. Bacteremia  Presence of viable microorganisms in the blood 
 3. SIRS a  Two or more of the following: 
  – Temperature  > 38 ° C or  < 36 ° C 
  – Heart rate  > 90 bpm 
  – Respiratory rate  > 20 bpm or PaCO 2  < 32 mm Hg 
  – White blood cell count  > 12,000/mm 3 or  < 4000/mm 3 or  > 10% band forms 
 4. Sepsis ( = 1 + 3)  Systemic response to infection 
 5. Severe sepsis  Sepsis and organ dysfunction, hypoperfusion, or hypotension 
  Manifestations of hypoperfusion may include but are not limited to 
  – Lactic acidosis 
  – Oliguria 
  – Acute alteration in mental status 
 6. Septic shock ( = 5 + 7)  Sepsis-induced hypotension, persisting despite adequate fluid resuscitation and manifestations of 
hypoperfusion as listed in 5 b,c 
 7. Hypotension, sepsis-induced  A decrease in systolic blood pressure to  < 90 mm Hg, or  > 40 mm Hg from baseline, in the absence of 
other cause for hypotension c 
 Table 1   Definitions for the septic syndromes adapted from the American College of Chest Physicians/Society of Critical Care Medicine 
expert panel [ 1 ] and reference [ 2 ].
 a SIRS may be caused by a variety of insults in addition to infection, including but not limited to trauma and status postmajor surgery, acute 
pancreatitis, and burns.  b An adequate fluid challenge is usually considered as at least 500 ml fluid infused rapidly and persisting hypoten-
sion as one persisting for >1 h.  c Patients on inotropic/vasoactive agents may not be hypotensive at time of evaluation. 
 – Acceptable to patient 
 – Stability in vivo and vitro 
 – Adequate analytical sensitivity (functional sensitivity) 
 – Good degree in reproducibility and accuracy 
 – Easy to perform 
 – Short analytical turnaround time 
 – Complete automation of assay 
 – International standardized 
 – Low cost 
 – Low biological variation 
 –  Reference range and cutoff values tested for gender, age, and 
ethnicity dependence 
 – Good diagnostic and prognostic accuracy 
 – Favorable cost-benefit ratio 
 Table 2   Desirable preanalytical, analytical, and postanalytical 
features of an ideal biomarker. 
specific setting of neonatal sepsis reporting that serum PCT 
at presentation presents a very good diagnostic accuracy 
(area under the curve = 0.87) for the diagnosis of neonatal 
sepsis. However, in view of the marked observed statistical 
heterogeneity, along with the lack of a uniform definition for 
neonatal sepsis, the interpretation of these findings should 
be done with appropriate caution [ 19 ]. 
 Cardiac dysfunction is a common complication of 
severe sepsis and septic shock; approximately 50% of 
patients with severe sepsis and septic shock seem to have 
any form of impairment of the left ventricular systolic func-
tion [ 9 ,  20 ]. Mortality from severe sepsis or septic shock 
ranges from 30% to 60%, with only a minor decline in mor-
tality over the last decades despite the aggressive treatment 
and the enormous costs invested in the ICUs [ 20 ]. As a result, 
the early recognition of myocardial dysfunction is crucial 
for the administration of the most appropriate therapy [ 9 , 
 20 ]. Cardiac troponins I and T and B-type-related natriu-
retic peptides (i.e., BNP and NT-proBNP) are the biomark-
ers re commended for the early and accurate detection of 
cardiac damage and myocardial dysfunction, respectively 
[ 21 ]. Several recent studies confirmed that the measurement 
of cardiac troponins and B-type-related natriuretic peptides 
could be useful in septic patients [ 9 – 11 ,  22 – 25 ]. These bio-
markers are usually elevated in patients with septic shock 
[ 9 – 11 ,  21 – 25 ] and predict an adverse outcome, especially 
natriuretic peptides [ 11 ,  22 ,  24 ,  25 ]. Moreover, monitoring 
BNP in early sepsis to identify occult systolic dysfunction 
might prompt the earlier use of inotropic agents [ 23 ]. 
 Acute kidney injury (AKI) is frequently observed with 
an incidence ranging from 20% to 25% and a high mor-
tality risk (approx. 70%) in patients with severe sepsis [ 12 , 
 26 ]. From a clinical point of view, it is important to note 
that the serum creatinine is unable to rapidly recognize 
AKI, because it rises slowly and reaches a steady state 
when the process of AKI has already initiated, so that there 
is compelling need for faster and more specific biomarkers 
[ 27 ]. Many biomarkers have been suggested for an accurate 
and early detection of AKI, but only neutrophil gelatinase-
associated lipocalin (NGAL), especially if assayed in urine 
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rather than in blood samples, is the most likely biomarker 
to be integrated into clinical practice in the near future 
[ 12 ,  26 ,  27 ]. According to Di Somma et al. [ 12 ], NGAL is 
increased in patients with sepsis, but its specific role in 
this condition is still controversial due to the potential 
confounding factor of extrarenal source of production [ 26–
29 ]. It should therefore be considered as a complementary 
marker during the course of sepsis for the diagnosis of AKI, 
helping PCT to manage the septic process. 
 Considering future remarks, Di Somma et al. [ 12 ] 
discuss in detail the other possible biomarkers for sepsis, 
including adrenomedullin and midregional proadreno-
medullin, some tyrosine kinase receptors (such as Mer 
receptors), and thrombopoietin. Among these novel bio-
markers, the measurement of ADM with new highly sensi-
tive immunoassay methods is suitable for routine use and 
can serve as a tool for the therapy monitoring in septic 
patients [ 30 ]. In addition, the immature granulocyte 
count and the granulocyte maturation index may improve 
the early diagnosis of septic state [ 31 – 33 ]. 
 At present, the combination of newer and older and 
well-known sepsis biomarkers (such as red blood cell dis-
tribution width), used as a multimarker approach, may 
be useful for emergency physicians to promptly identify 
sepsis and improve the diagnosis, identification of organ 
dysfunction, treatment, and risk stratification. Despite 
major promises, however, all the steps of the translation 
process need to be respected and robust evidence should 
be collected to demonstrate unquestionable favorable 
health impacts of these new biomarkers before their intro-
duction in clinical practice. 
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